Moderna files application for review of updated Covid-19 vaccine – Pharmaceutical Technology

Moderna has filed an application with the US Food and Drug Administration (FDA) to review its updated Spikevax formula, designed to combat the SARS-CoV-2 variant JN.1, for the 2024 to 2025 season.

The move follows guidance from the FDA recommending an update to Covid-19 vaccines to include the monovalent JN.1 composition.

The recommendation was unanimously supported by the Vaccines and Related Biological Products Advisory Committee during a meeting held on 5 June 2024.

It aligns with theguidance from the World Health Organization Technical Advisory Group on Covid-19 Vaccine Composition and the European Medicines Agencys Emergency Task Force on the use of Covid-19 vaccines targeting the JN.1 variant.

The most common local adverse event linked to the updated Covid-19 vaccine of Moderna was pain at the injection site.

Systemic adverse events reported include headache, fatigue, myalgia and chills.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Country * UK USA Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Cte d"Ivoire Croatia Cuba Curaao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Runion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

These findings are critical as Moderna aims to secure global regulatory approval and supply the vaccine in time for the next vaccination season.

While the updated Spikevax vaccine for the 2024 to 2025 season is under review, the current 2023 to 2024 formula has been authorised for emergency use in individuals aged six months to 11 years.

The Spikevax vaccine is indicated for active immunisation against Covid-19 in individuals aged 12 years and above.

Moderna CEO Stphane Bancel stated: For four years, Moderna has consistently delivered vaccines that offer protection against Covid-19, and work is well underway to provide a vaccine targeting JN.1.

Staying up to date with your Covid-19 vaccine remains one of the best ways to protect yourself during the upcoming respiratory illness season.

The latest submission comes on the heels of Modernas recent success in securing FDA approval for its mRNA-based respiratory syncytial virus (RSV) vaccine, mRESVIA, for adults aged 60 and above.

Give your business an edge with our leading industry insights.

See more here:

Moderna files application for review of updated Covid-19 vaccine - Pharmaceutical Technology